Treatment of multiple myeloma bone disease: experimental and clinical data
| Autor: | Zakareya Gamie, Kyriakos A. Papavasiliou, Michael Potoupnis, John Kyrkos, Eustathios Kenanidis, Yvonne Mary Papamerkouriou, Eleftherios Tsiridis, I Sarris, Thomas Kostakos |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Bone disease Clinical Biochemistry Pamidronate Antineoplastic Agents Bone Neoplasms Antibodies Monoclonal Humanized Zoledronic Acid Osteoclast Internal medicine Drug Discovery medicine Animals Humans Survival rate Multiple myeloma Pharmacology Diphosphonates business.industry Imidazoles medicine.disease medicine.anatomical_structure Proteasome Immunology Quality of Life Bone Diseases Denosumab business Multiple Myeloma |
| Zdroj: | Expert opinion on biological therapy. 15(2) |
| ISSN: | 1744-7682 |
| Popis: | Bone disease is present in the majority of patients with multiple myeloma and can seriously affect quality of life and survival rate. In addition to suppression of osteoclastogenesis, there have been developments made in terms of the therapeutic agents available, such as novel immunomodulating agents, proteasome and receptor activator of nuclear factor κB ligand inhibitors.AREAS COVERED include in vitro, in vivo and clinical evidence was collected using MEDLINE (1950 - May 2014), EMBASE (1980 - May 2014) and Google Scholar (1980 - May 2014) databases.Bisphosphonates are the mainstay of myeloma bone disease treatment. Oral clodronate and intravenous pamidronate and zoledronic acid are currently used drugs and seem to have comparable results in preventing skeletal-related events of the disease. Zoledronate can also have survival benefits and based on the available evidence is the superior bisphosphonate; however, its side effects have to be monitored. Denosumab had comparable results with zoledronate on myeloma bone disease treatment; its use has not been completely proven yet. There is an expanding set of drugs, proteasome inhibitors, under investigation with great potential to reduce the negative effects of myeloma cells on bone. Future clinical studies should compare both the catabolic and anabolic effects of these agents on bone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|